A comprehensive review published in Frontiers in Pharmacology examines the pharmacological effects and mechanisms of borneol and borneol-containing formulations in central nervous system diseases. The study, authored by researchers from the Encephalopathy Center at the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, integrates existing evidence to compare how borneol influences various pathophysiological processes across different neurological conditions. The review highlights that while borneol is widely used in traditional Chinese medicine, its specific therapeutic value and long-term safety remain areas requiring rigorous investigation.
Borneol is an aromatic medicinal agent that serves both as a standalone component and as an ingredient in multi-herb formulations. Its relevance to central nervous system disorders has attracted increasing attention, particularly in the context of Alzheimer’s disease, Parkinson’s disease, epilepsy, ischemic stroke, and glioma. The review notes that accumulating evidence suggests borneol may influence multiple pathophysiological processes, including brain-barrier function and drug delivery, neuroinflammation and oxidative stress, neurotransmitter homeostasis and neuronal excitability, cellular injury and death, and the clearance of pathological substances and post-injury repair.
The authors integrate and compare these mechanisms across different disease contexts to identify patterns and discrepancies. A notable finding is that while several actions of borneol appear to converge across central nervous system disorders, others are strongly disease- and context-dependent. For instance, the effects of borneol on brain-barrier permeability, oxidative stress, and cell death may differ in direction depending on the specific disease pathology and the intended therapeutic outcome.
Pharmacokinetic studies support measurable brain exposure to borneol. However, the review points out that direct comparative evidence regarding pharmacological activity, brain disposition, and human pharmacokinetics among borneol preparations of different botanical origins and stereochemical configurations remains scarce.
Borneol-containing formulations exhibit multi-level pharmacological effects, but the review emphasizes a significant limitation in the current evidence base. Most studies lack borneol-alone, borneol-depleted, or add-back controls, which means that the observed effects cannot be unequivocally attributed to borneol itself.
The current evidence base is dominated by cellular and animal studies, with several proposed mechanisms inferred primarily from changes in molecular expression or computational predictions. The review notes that robust causal validation, high-quality clinical evidence, and long-term safety data are still limited.
Future studies should focus on defining the dose–exposure–response relationships and disease-specific therapeutic windows of different borneol preparations. Additionally, research is needed to establish the independent contribution of borneol within complex formulations, which will clarify its specific role in multi-herb treatments. The review calls for rigorous mechanistic and clinical investigation to determine the genuine therapeutic value and long-term safety of borneol.
Subject of Research: Pharmacological effects and mechanisms of borneol in central nervous system diseases
Article Title: Recent advances in the pharmacological effects and mechanisms of borneol and borneol-containing formulations in central nervous system diseases
Article References: Zhang, X., Wu, Y., Han, J., Zhao, Z., Yao, Y., Sun, Y., & Wang, X. (2026). Recent advances in the pharmacological effects and mechanisms of borneol and borneol-containing formulations in central nervous system diseases. Frontiers in Pharmacology, 17, Article 1950139. https://doi.org/10.3389/fphar.2026.1950139
Image Credits: AI Generated
DOI: 10.3389/fphar.2026.1950139
Keywords: borneol, central nervous system, pharmacology, traditional Chinese medicine, neuroinflammation, Alzheimer's disease, Parkinson's disease, drug delivery, pharmacokinetics, review, Recent, advances
News Source: Cassandra Pierce. (November 10, 2026). Review: Borneol’s Complex CNS Mechanisms and Evidence Gaps. Scienmag.



